ArticleJournal of hematology2020

Outcomes of Reduced Frequency Dosing of Ibrutinib in Chronic Lymphocytic Leukemia Patients Following Complete or Partial Remission: A Pilot Study.

William Alexander et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.